REVERSED INNOVATION
We find new indications
for existing technologies

THE MEANING OF
REVERSED INNOVATION
We find new indications for existing technologies.
Through our research, we work relentlessly to improve lives by addressing unmet medical needs.
Reversed Innovation is our core value.
As a leader in the biopharmaceutical industry, reversed innovation aligns with the broader theme, as we take an existing product or technology and use it to address a new or previously overlooked or unconsidered medical problem or condition.

TRUSTED DEVELOPMENT
Dr. Claus J. Møller-San Pedro is the company CEO.
Dr. Møller co-founded and secured successful IPOs of 3 companies in the BioPharma Industry: OXiGENE Inc. (OTLC); Genmab A/S (GMAB) and Y-mAbs Therapeutics, Inc. (YMAB).
Our latest investor presentation is always available here together with annual reports, financial information and other news from AFYX.
NEWS
Two exciting job opportunities at our Hørsholm offices
AFYX Therapeutics is a growing and we have two exciting job opportunities inside Finance & Accounting and Office & Warehouse Administration, respectively. See job posts directly on LInkedIn: Financial Accountant, Copenhagen Area (Hørsholm) Office &...
Cevidra SAS and AFYX Therapeutics A/S announce distribution and collaboration agreement
Hørsholm, Denmark – January 13, 2025 AFYX Therapeutics A/S and Cevidra SAS are pleased to announce a strategic partnership aimed at bringing innovative treatments for Head and Neck Cancer to the French market. Under this collaboration, Cevidra will serve as the local...
Er-Kim and AFYX Therapeutics A/S announce distribution and sales collaboration
Hørsholm, Denmark – January 6, 2025 Er-Kim and AFYX Therapeutics A/S announced today a distribution and sales collaboration for two AFYX products. The two companies have entered a mutual sales and distribution collaboration where Er-Kim will sell and distribute the...
AFYX THERAPEUTICS HQ
Slotsmarken 11, 1.tv.
DK-2970 Hørsholm
Denmark
VAT: 38793594
Phone: +45 7174 7174
info@afyxtx.com
INPHENA NORWAY
Gaustadalléen 21
NO-0349 Oslo
Norway
VAT: 922 558 221
Phone: +47 2396 7174